Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.

FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.

During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.

Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.

Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.

FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.

Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.